Scholar Rock Holding Stock Price, News & Analysis

Scholar Rock (SRRK) announced positive Phase 2 EMBRAZE trial results for apitegromab combined with tirzepatide for weight loss. The study showed that apitegromab preserved 54.9% more lean mass (+4.2 lbs) compared to tirzepatide alone (p=0.001). Patients receiving the combination therapy lost 12.3% body weight with better quality weight loss (85% fat mass/15% lean mass) versus tirzepatide alone (70% fat mass/30% lean mass). The combination resulted in 18.8 lbs fat mass loss compared to 17.7 lbs with tirzepatide alone. The drug demonstrated a favorable safety profile with no serious adverse events related to apitegromab treatment. While promising for the platform, the company remains focused on apitegromab's potential approval for spinal muscular atrophy (SMA) and plans to file an IND for SRK-439 in H2 2025.

Scholar Rock (SRRK) announced equity inducement grants to 11 new employees, including stock options for 176,963 shares and restricted stock units for 132,737 shares under its 2022 Inducement Equity Plan. The stock options have an exercise price of $34.07, equal to the closing price on June 9, 2025. The options vest 25% after one year and the remaining 75% quarterly over three years, while restricted stock units vest in four equal annual installments. These grants are specifically designed for new hires as employment incentives under Nasdaq Rule 5635(c)(4). Scholar Rock is a late-stage biopharmaceutical company developing apitegromab for spinal muscular atrophy and other neuromuscular diseases.

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company specializing in apitegromab development for spinal muscular atrophy (SMA) and other neuromuscular diseases, announced its participation in the 46th Annual Goldman Sachs Global Healthcare Conference. CEO David L. Hallal and management team members will engage in a fireside chat on June 11, 2025, at 9:20 a.m. ET in Miami, Florida. The presentation will be accessible via live webcast through the company's Investors & Media section, with replay availability for approximately 90 days.

Scholar Rock (SRRK) has appointed Rebecca McLeod as Chief Brand Officer and U.S. General Manager to lead the anticipated U.S. commercial launch of apitegromab for spinal muscular atrophy (SMA) patients. McLeod, a 25-year industry veteran, previously served as argenx U.S. General Manager where she successfully led the launch of VYVGART for gMG and CIDP. In her new role, she will be responsible for establishing global brand strategy and market positioning for apitegromab across Europe, Asia-Pacific, and Latin America. McLeod's extensive experience includes leadership positions at Alexion Pharmaceuticals and Takeda Pharmaceuticals, with her most recent achievement being one of the most successful biopharmaceutical franchise launches with VYVGART at argenx.

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company specializing in developing apitegromab for spinal muscular atrophy (SMA) and other neuromuscular diseases, announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO David L. Hallal and the management team will engage in a fireside chat on June 4 at 3:45 p.m. ET in New York City. The presentation will be accessible via live webcast through Scholar Rock's Investors & Media website section, with replay availability for approximately 90 days.

Scholar Rock (SRRK), a late-stage biopharmaceutical company focused on developing apitegromab for spinal muscular atrophy (SMA), has granted inducement equity awards to 14 new employees. The awards include 60,400 shares in stock options with an exercise price of $32.46 and 45,300 shares in restricted stock units.

The stock options will vest 25% after one year from each employee's start date, with the remaining 75% vesting in 12 quarterly installments. The restricted stock units will vest in four equal annual installments. These awards were granted under the Company's 2022 Inducement Equity Plan, specifically designed for new hires as per Nasdaq Listing Rule 5635(c)(4).

Scholar Rock (SRRK) reported Q1 2025 financial results and significant progress in its drug development programs. The FDA has accepted their BLA for apitegromab with priority review for Spinal Muscular Atrophy (SMA), setting a PDUFA date of September 22, 2025. The European Medicines Agency also validated their Marketing Authorization Application. The company reported a net loss of $74.7 million ($0.67 per share) and holds $364.4 million in cash and equivalents, expected to fund operations into 2027. Key upcoming milestones include topline results from the Phase 2 EMBRAZE obesity trial in June 2025, initiation of the Phase 2 OPAL trial in SMA in Q3 2025, and an IND application for SRK-439 in Q3 2025. The company has strengthened its leadership team with strategic appointments in preparation for commercial launch.

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company specializing in treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, has scheduled a conference call for May 14, 2025, at 8:15am ET. The call will cover the company's first quarter 2025 financial results and provide a business update.

Participants can join via telephone by pre-registering through the provided link, after which they will receive dial-in details. The call will also be available as a live audio webcast in the Investor Relations section of Scholar Rock's website. A replay will remain accessible on the company website for approximately 90 days.

Scholar Rock (SRRK) announced equity inducement grants to two new executive hires. R. Keith Woods (Chief Operating Officer) and Vikas Sinha (Chief Financial Officer) received awards covering up to 1,420,134 total shares, including: - 110,067 stock options each (exercise price: $32.91) - 100,000 restricted stock units (RSUs) each - Up to 500,000 performance-based RSUs (PSUs) each The stock options will vest 25% after one year, with remaining 75% vesting quarterly over 3 years. RSUs will vest in 4 equal annual installments. PSUs are subject to performance and time-based conditions. All awards were granted under the company's 2022 Inducement Equity Plan for new employees.